New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2013
06:07 EDTCHL, AAPL, BRK.A, DISH, CLWR, WFC, USB, BATS, S, BAC, JPM, C, MS, GSOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: BATS Global Markets (BATS) said that a "system issue" allowed hundreds of thousands of transactions in a four-year period to be executed at prices that may have violated securities rules. SEC rules require orders to go to the best bid or offer in the market, the Wall Street Journal reports...Major banks pushed to complete an $8.5B legal settlement with federal regulators last weekend so they could book the deal's costs in their Q4 results and present a cleaner slate to investors in 2013, sources say, the Wall Street Journal reports...REUTERS: Sprint Nextel (S) is under no pressure to raise its $2B offer for Clearwire (CLWR) to beat a higher bid by Dish Network (DISH) as it holds several trump cards it can play to thwart its rival, sources say, Reuters reports...Apple (AAPL) CEO Tim Cook met with China Mobile (CHL) Chairman Xi Guohua today to discuss "matters of cooperation," a China Mobile spokesman said, raising hopes that a deal between the two may move forward, Reuters reports...BLOOMBERG: Berkshire Hathaway’s (BRK.A) Warren Buffett, who oversees stakes in some of the largest U.S. banks, said the nation’s lenders have rebuilt capital to the point where they no longer pose a threat to the economy, Bloomberg reports...The $500B market for leveraged loans, one of the last to depend on facsimile machines, is turning to computers to save time and money as stock, bond and commodities exchanges have done for years. More than four million faxes with information ranging from quarter-end payments to interest rates were received by loan custodians in 2012, Bloomberg reports.
News For A From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 24, 2015
16:20 EDTAAgilent to host analyst meeting
Subscribe for More Information
May 20, 2015
16:29 EDTAAgilent appoints Rodney Gonsalves as principal accounting officer
Subscribe for More Information
May 18, 2015
19:12 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
May 15, 2015
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use